Veracyte Inc’s recent filing unveils that its Chief Commercial Officer-CLIA Leite John unloaded Company’s shares for reported $0.23 million on Mar 07 ’25. In the deal valued at $31.66 per share,7,411 shares were sold. As a result of this transaction, Leite John now holds 100,249 shares worth roughly $2.8 million.
Then, JOHN LEITE bought 7,411 shares, generating $240,932 in total proceeds.
Before that, ANN MCGUIRE bought 1,142 shares. Veracyte Inc shares valued at $38,326 were divested by the Officer at a price of $33.56 per share.
Craig Hallum initiated its Veracyte Inc [VCYT] rating to a Buy in a research note published on March 20, 2025; the price target was $45. A number of analysts have revised their coverage, including Goldman’s analysts, who decreased its forecast for the stock in early December from “a Buy” to “a Neutral”. Wolfe Research began covering VCYT with “an Outperform” recommendation on November 15, 2024. UBS started covering the stock on October 16, 2024. It rated VCYT as “a Buy”.
Price Performance Review of VCYT
On Tuesday, Veracyte Inc [NASDAQ:VCYT] saw its stock jump 2.98% to $27.97. Over the last five days, the stock has lost -3.55%. Veracyte Inc shares have fallen nearly -29.37% since the year began. Nevertheless, the stocks have risen 29.37% over the past one year. While a 52-week high of $47.32 was reached on 01/30/25, a 52-week low of $19.73 was recorded on 05/23/25. SMA at 50 days reached $30.45, while 200 days put it at $35.34.
Levels Of Support And Resistance For VCYT Stock
The 24-hour chart illustrates a support level at 27.48, which if violated will result in even more drops to 26.98. On the upside, there is a resistance level at 28.22. A further resistance level may holdings at 28.46. The Relative Strength Index (RSI) on the 14-day chart is 40.47, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.49, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 76.67%. Stochastics %K at 13.88% indicates the stock is a buying.
The most recent change occurred on October 10, 2024 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $40 price target.
